| 1. |
Tacrolimus cost study provokes"sheer puzzlement" |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1464,
2004,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 2. |
Uncertainty over the modelled costs of inhaled corticosteroids in COPD |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1464,
2004,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 3. |
How to expand HAART use in poor countries |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1464,
2004,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 4. |
Varicella vaccination lowers hospitalisations, costs in the US |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1464,
2004,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 5. |
Capecitabine saves time and money in colon cancer |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1464,
2004,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 6. |
Conivaptan effective in hyponatraemia |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1464,
2004,
Page 7-8
S Sullivan,
Preview
|
|
摘要:
Conivaptan [YM 087] increases serum sodium levels and effective water clearance in patients with hyponatraemia, according to studies presented at the Annual Scientific Sessions of the American Heart Association (AHA) [New Orleans, US; November 2004]. Oral conivaptan was shown to increase the serum sodium AUC and serum sodium levels in patients with euvolaemia or hypervolaemia in two studies. Similar improvements in serum sodium levels were observed in a third study, which evaluated the efficacy of IV conivaptan.
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 7. |
Antivenin comparison: which is best for snake bites in Ecuador? |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1464,
2004,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 8. |
Olanzapine*may be effective for the prevention of delayed emesis in chemotherapy recipients, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1464,
2004,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 9. |
Hydralazine/isosorbide dinitrate beneficial in A-HeFT study |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1464,
2004,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 10. |
Reviparin reduces reinfarction, mortality after MI |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1464,
2004,
Page 11-12
S Sullivan,
Preview
|
|
摘要:
Reviparin sodium [Clivarin] reduces the incidences of mortality and reinfarction in patients who have had a myocardial infarction (MI), according to a study presented at the Annual Scientific Sessions of the American Heart Association (AHA) [New Orleans, US; November 2004]. Patients with ST-segment elevation or new bundle branch block receiving reviparin for 7 days post-MI experienced a significant reduction in the rates of mortality and reinfarction, compared with placebo recipients. Furthermore, the benefits observed with reviparin were maintained for 30 days during the post-MI period."The reduction in mortality with Reviparin is truly remarkable since no other drug in this class has shown similar benefits and the fact the drug was tested on top of already proven therapies,"said Dr Shamir Mehta, from McMaster University, Hamilton, Canada.
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
首页
